Komori
Fuso Pharmaceutical Industries (4538) · PolicyRestated

Funding policy to finance capital investment and research and development through operating cash flow and borrowings

First written in FY2018. 4 of 5 entries say "Restated". Latest entry: FY2024.

5entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018 – FY20242018: 120182019: 120192020: 020202021: 120212022: 120222023: 020232024: 12024
Same theme, other companies
Capital allocation policy balancing future investment and shareholder dividendsA theme 457 companies write about · 0 as a headwind · 459 as a tailwind

80 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 461 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「The Company plans to meet these funding needs through cash flow from operating activities and internal funds, as well as financing through borrowings from financial institutions in light of its production facility investment and research and development plans.」

    The Company continues its policy of funding capital investment and research and development through operating cash flow, internal funds, and borrowings from financial institutions.
  2. FY2022RestatedAnnual report

    「The Company plans to meet these funding needs through cash flow from operating activities and internal funds, as well as financing through borrowings from financial institutions in light of its production facility investment and research and development plans.」

    The Company continues to fund capital investment and research and development through operating cash flow, internal funds, and borrowings from financial institutions.
  3. FY2021RestatedAnnual report

    「The Company plans to meet these funding needs through cash flow from operating activities and internal funds, as well as financing through borrowings from financial institutions in light of its production facility investment and research and development plans.」

    The Company continues to fund capital investment and research and development through operating cash flow, internal funds, and borrowings from financial institutions.
  4. FY2019RestatedAnnual report

    「The Company plans to meet these funding needs through cash flow from operating activities and internal funds, as well as financing through borrowings from financial institutions in light of its production facility investment and research and development plans.」

    The Company continues to fund capital investment and research and development through operating cash flow, internal funds, and borrowings from financial institutions.
  5. FY2018First statedAnnual report

    「The Company plans to meet these funding needs through cash flow from operating activities and internal funds, as well as financing through borrowings from financial institutions in light of its production facility investment and research and development plans.」

    The Company plans to fund the costs of manufacturing, capital investment, development of dialysis care, and research and development in new fields through operating cash flow, internal funds, and borrowings from financial institutions.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Funding policy to finance capital investment and research and development through operating cash flow and borrowings | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori